VF
SYRS

Virtu Financial’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Virtu Financial’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-32,791
Closed -$8K – 2209
2024
Q4 		$8K Buy
32,791
+13,162
+67% +$15.8K ﹤0.01% 1410
2024
Q3 		$42K Buy
+19,629
New +$70.5K ﹤0.01% 1044
2024
Q2 		– Sell
-12,030
Closed -$64K – 1999
2024
Q1 		$64K Buy
+12,030
New +$83.2K ﹤0.01% 985
2023
Q1 		– Sell
-12,428
Closed -$45K – 2211
2022
Q4 		$45K Buy
+12,428
New +$53.9K 0.01% 1102
2022
Q3 		– Sell
-1,183
Closed -$11K – 2340
2022
Q2 		$11K Sell
1,183
-69
-6% -$645 ﹤0.01% 1421
2022
Q1 		$15K Buy
+1,252
New +$22.4K ﹤0.01% 1338
2021
Q4 		– Sell
-2,094
Closed -$94K – 2271
2021
Q3 		$94K Buy
+2,094
New +$102K 0.01% 1161
2021
Q2 		– Sell
-3,399
Closed -$254K – 2169
2021
Q1 		$254K Buy
+3,399
New +$353K 0.02% 914
2018
Q1 		– Sell
-1,966
Closed -$191K – 2738
2017
Q4 		$191K Buy
+1,966
New +$264K 0.01% 1707

Other funds holding SYRS

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $339M AUM 120.53% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Virtu Financial's SYRS Position: Q1 2025 in Review

Virtu Financial sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 32,791 shares — an estimated $8K sold.

Virtu Financial first reported a position in SYRS in Q4 2017 and held it in 9 quarters. The position peaked at $254K in Q1 2021. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.

  • Virtu Financial reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Virtu Financial sold 32,791 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $8K.
  • Virtu Financial first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 9 quarters.
  • Virtu Financial's Syros Pharmaceuticals, Inc. Common Stock position peaked at $254K in Q1 2021.
  • 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.

Based on Virtu Financial's 13F filing for Q1 2025, filed 12 May 2025.